Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme.

Chai SY, Perich R, Jackson B, Mendelsohn FA, Johnston CI.

Clin Exp Pharmacol Physiol Suppl. 1992;19:7-12.

PMID:
1327597
2.

Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.

Johnston CI, Fabris B, Yamada H, Mendelsohn FA, Cubela R, Sivell D, Jackson B.

J Hypertens Suppl. 1989 Sep;7(5):S11-6. Review. Erratum in: J Hypertens Suppl 1991 Jun;9(6):following H30.

PMID:
2553899
3.

Experience with perindopril in normal volunteers.

Waeber B, Nussberger J, Perret L, Santoni JP, Brunner HR.

Arch Mal Coeur Vaiss. 1989 May;82 Spec No 1:35-41. Review.

PMID:
2549899
4.

Angiotensin-converting enzyme inhibition: prospects for the future.

Jackson B, Mendelsohn FA, Johnston CI.

J Cardiovasc Pharmacol. 1991;18 Suppl 7:S4-8. Review.

PMID:
1725200
6.

Transdermal delivery of Angiotensin Converting Enzyme inhibitors.

Helal F, Lane ME.

Eur J Pharm Biopharm. 2014 Sep;88(1):1-7. doi: 10.1016/j.ejpb.2014.03.007. Epub 2014 Mar 20. Review.

PMID:
24657822
7.

Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

MacFadyen RJ, Lees KR, Reid JL.

Br J Clin Pharmacol. 1991 Jan;31(1):1-13. Review.

8.

The present molecules of converting enzyme inhibitors.

Brunner HR, Nussberger J, Waeber B.

J Cardiovasc Pharmacol. 1985;7 Suppl 1:S2-11. Review.

PMID:
2580170
9.

The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.

Kaur P, Muthuraman A, Kaur M.

ACS Chem Neurosci. 2015 Apr 15;6(4):508-21. doi: 10.1021/cn500363g. Epub 2015 Feb 24. Review.

PMID:
25680080
10.
12.

Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Macfadyen RJ, Lees KR, Reid JL.

Drugs. 1990;39 Suppl 1:49-63. Review.

PMID:
2407493
13.
15.

Perindopril (Coversyl)--a new ACE inhibitor. Perindopril--a review of its pharmacokinetics and clinical pharmacology.

Reid JL, Macfadyen RJ, Lees KR.

S Afr Med J. 1991 Oct 5;Suppl:1-5. Review. No abstract available.

PMID:
1925812
16.

Drug-patient interactions and their relevance in the treatment of heart failure.

Johnston D, Duffin D.

Am J Cardiol. 1992 Oct 8;70(10):109C-112C. Review.

PMID:
1329465
17.

[Angiotensin converting enzyme].

Kokubu T, Takada Y.

Nihon Rinsho. 1982;40(9):1956-63. Review. Japanese. No abstract available.

PMID:
6296486
18.

Pharmacokinetics of perindopril in high-risk populations.

Resplandy G, Genissel P.

J Cardiovasc Pharmacol. 1991;18 Suppl 7:S9-18. Review.

PMID:
1725203
19.

High-dose ACE inhibition: can it improve renoprotection?

Navis G, Kramer AB, de Jong PE.

Am J Kidney Dis. 2002 Sep;40(3):664-6. Review. No abstract available.

PMID:
12200823
20.

Pharmacokinetics of angiotensin converting enzyme inhibitors in plasma and tissue using radioinhibitor binding and displacement assays.

Johnston CI, Jackson B, Cubela R, Sivell D, Kozhuki M.

Adv Exp Med Biol. 1989;247A:29-34. Review. No abstract available.

PMID:
2557744

Supplemental Content

Support Center